FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Foghorn Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.87+0.02 (+1.08%)
Close on Oct 19, 2026
- Market cap
- $132.08M
- P/E (TTM)
- –
- Dividend yield
- –
Foghorn Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Market Cap | $111.05M | $164.85M |
| Enterprise Value | $42.97M | $87.06M |
| PS Ratio | 3.02 | 3.60 |
Enterprise value
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 1.17 | 2.43 |
Income (trailing twelve months)
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Revenue | $36.74M | $57.94M |
| Operating Income | -$72.76M | -$21.44M |
| Net Income | -$64.58M | -$22.46M |
| EBITDA | -$70.62M | -$16.91M |
| EPS (Diluted) | -$0.98 | -$0.83 |
Margins
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -198.0% | -44.5% |
| Profit Margin | -175.8% | -39.2% |
| EBITDA Margin | -192.2% | -31.3% |
| FCF Margin | -229.4% | -8.85% |
Returns
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -30.1% | -41.0% |
| Return on Capital Employed (ROCE) | -47.6% | -37.8% |
Growth
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 52.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 17.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 135.1% | 6.42% |
Balance sheet
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $68.08M | $62.42M |
| Net Cash (Debt) | $68.08M | $15.68M |
| Net Cash Per Share | $1.15 | $0.66 |
| Equity (Book Value) | -$81.04M | $48.79M |
| Book Value Per Share | -$1.36 | $1.36 |
| Tangible Book Value | -$81.04M | $23.06M |
| Working Capital | $119.47M | $75.77M |
Financial position
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.36 | 3.30 |
| Quick Ratio | 1.35 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$84.24M | -$12.35M |
| Capital Expenditures | -$50.00K | -$1.06M |
| Free Cash Flow | -$84.29M | -$20.28M |
| FCF Per Share | -$1.42 | -$0.42 |
Efficiency
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.17 | 0.38 |
| Revenue Per Employee | $346.59K | $398.96K |
| Profits Per Employee | -$609.24K | -$703.34K |
| Employee Count | 106 | 74 |
Dividends and yields
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -58.2% | -22.7% |
| FCF Yield | -75.9% | -9.07% |
Shares
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 59,385,300 | 58,179,650 |
| Shares Change (YoY) | 5.95% | 11.1% |
| Shares Change (QoQ) | 0.01% | 0.54% |
| Float | 37,840,600 | 49,173,100 |
| Shares Held by Insiders | 36.3% | 11.6% |
| Shares Held by Institutions | 75.6% | 59.4% |
Scores
| Measure | Foghorn Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -4.60 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Foghorn Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.